Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: A prerequisite for adoptive cell transfer

Cytotherapy

Volumn 13, Issue 7, 2011, Pages 822-834

  Junker, Niels ^a   Andersen, Mads Hald ^a   Wenandy, Lynn ^a   Dombernowsky, Sarah Louise ^a   Kiss, Katalin ^b   Sørensen, Christian Hjort ^b   Therkildsen, Marianne Hamilton ^c   Von Buchwald, Christian ^c   Andersen, Elo ^a   Straten, Per Thor ^a   Svane, Inge Marie ^a  

^a Mental Health Services CPH   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Adoptive T cell therapy; Head and neck squamous cell carcinoma; Tumor infiltrating lymphocyte expansion; Tumor infiltrating lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ADULT; AGED; ARTICLE; CANCER PATIENT; CELL EXPANSION; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MALE; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 84860389787     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.563291     Document Type: Article

References (42)

1. Survival of Cancer Patients in Europe: The EUROCARE-2 study. IARC Sci Publ. 1999;151:1-572.
2. Gibson MK, Forastiere AA. Multidisciplinary approaches in the management of advanced head and neck tumors: State of the art. Curr Opin Oncol. 2004;16:220-4.
3. Clark WH. Tumour progression and the nature of cancer. Br J Cancer. 1991;64:631-44.
4. Hald J, Rasmussen N, Claesson MH. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother. 1995;41:243-50.
5. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumorinfiltrating lymphocytes and interleukin-2. J Clin Oncol. 1994;12:1475-83.
6. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005;28:258-67.
7. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res. 2003;9:4296-303.
8. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 2007;67:8865-73.
9. Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease. Clin Cancer Res. 2008;14:3706-15.
10. Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007;25:1562-9.
11. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-74.
12. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280-90.
13. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol. 2004;165:1853-63.
14. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
15. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269-74.
16. Hald J, Rasmussen N, Claesson MH. In vivo infi ltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumourinfiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells. Cancer Immunol Immunother.1994;39:383-90.
17. Whiteside TL, Heo DS, Takagi S, Johnson JT, Iwatsuki S, Herberman RB. Cytolytic antitumor effector cells in longterm cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother. 1988;26:1-10.
18. S traathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005; 105:1898-904.
19. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, et al. Adoptive transfer of cytomegalovirusspecific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-86.
20. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-57.
21. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26:5233-9.
22. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159-66.
23. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175: 7046-52.
24. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173: 7125-30.
25. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332-42.
26. thor Straten P, Guldberg P, Gronbaek K, Hansen MR, Kirkin AF, Seremet T, et al. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol. 1999;163:443-7.
27. Guldberg P, Guttler F. 'B road-range'DGGE for single-step mutation scanning of entire genes: Application to human phenylalanine hydroxylase gene. Nucleic Acids Res. 1994;22: 880-1.
28. thor Straten P, Kirkin AF, Siim E, Dahlstrom K, Drzewiecki KT, Seremet T, et al. Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. Clin Immunol. 2000;96:94-9.
29. Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, et al. Immunogenicity of Bcl-2 in patients with cancer. Blood. 2005;105:728-34.
30. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169:1984-92.
31. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: Association with clinical outcome. Clin Cancer Res. 2005;11:2552-60.
32. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294-305.
33. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 2005;105:241-50.
34. Desfrancois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, Dreno B, et al. Double positive CD4 CD8 alpha beta T cells: A new tumor-reactive population in human melanomas. PLoS One. 2010;5:e8437.
35. Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: Importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol. 2006;176:7726-35.
36. Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31:742-51.
37. Whiteside TL. Anti-tumor vaccines in head and neck cancer: Targeting immune responses to the tumor. Curr Cancer Drug Targets. 2007;7:633-42.
38. Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, et al. Identifi cation of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med. 2001;194:1313-23.
39. Sorensen RB, Andersen RS, Svane IM, Engell-Noerregaard L, Hadrup SR, Balslev E, et al. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin Cancer Res. 2009;15:1543-9.
40. Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol. 2009;21:190-9.
41. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lymphodepleting chemotherapy regimen in metastatic melanoma patients. J Immunother. 2009;32:415-23.
42. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995;42:455-500.